Aerie Pharmaceuticals reported a net loss of $32.4 million, or $0.89 per share, in 2017’s third quarter compared with a net loss of $23.8 million, or $0.81 per share, in the same quarter last year, according to a press release.
Total operating expenses were $32.2 million, which includes $12.4 million in research and development costs and $19.8 million in selling, general and administrative costs, whereas 2016’s third quarter operating expenses totaled $23.8 million. The increase was attributed to more activities to support the growth of operations and preparation for
Uncategorized